Patents Assigned to Merck
  • Patent number: 10323090
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 18, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, David Vlerick, Robert A. Kastelein
  • Patent number: 10326090
    Abstract: The present invention relates to a semiconductor composition including an inorganic semiconducting material and an organic binder. The present invention further relates to an electronic device comprising a semiconducting layer consisting of such semiconductor composition.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 18, 2019
    Assignee: Merck Patent GmbH
    Inventors: Klaus Bonrad, Matthias Rehahn, Nicole Kolmer-Anderl, Paul Mundt
  • Publication number: 20190177617
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG1, MG2, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and in particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: May 11, 2017
    Publication date: June 13, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Kevin ADLEM, Patricia SAXTON, Hassan ARASI
  • Publication number: 20190177326
    Abstract: The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Francois-Rene Alexandre, Rachid Rahali, Izzat Raheem, Christophe Parsy
  • Publication number: 20190175744
    Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 13, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Chunhui Huang, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Qiaolin Deng, Elisabetta Bianchi, Federica Orvieto
  • Publication number: 20190176154
    Abstract: The present invention relates to a vessel comprising a device, said device being a sensor or an information storage device or both, and a communication means to transfer data from said vessel to a receiver. The present application also relates to a system, for example a storage system, comprising such vessel.
    Type: Application
    Filed: June 2, 2017
    Publication date: June 13, 2019
    Applicant: Merck Patent GmbH
    Inventors: Brian DANIELS, James KUGLER, Owen LOZMAN, Wiebke DONDRAS, Toby CULL, Mark JAMES, Gerald MUELLER
  • Publication number: 20190175602
    Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetra-cyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: August 14, 2017
    Publication date: June 13, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, LING Tong, Joseph A. Koziowski, Craig: A Coburn, De-yi J. Yang, Deyou Sha, Jae-Hun. Kim, Michael Dwyer, Kartik M. Keertikar, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang
  • Publication number: 20190177393
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: May 23, 2017
    Publication date: June 13, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
  • Publication number: 20190177618
    Abstract: The present invention relates to a liquid crystalline medium which comprises one or more mesogenic compounds selected from the group of compounds of formulae I and II as set forth in claim 1, one or more chiral compounds and one or more polymerisable compounds, to a composite system obtained from or respectively obtainable from the medium by polymerising the one or more polymerisable compounds, and to liquid crystal displays comprising the composite system, in particular displays operating in reflective mode. The present invention further relates to a process for preparing the composite system comprising spatially selective polymerisation.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 13, 2019
    Applicant: Merck Patent GmbH
    Inventors: Dong-Mee SONG, Yong-Hyun CHOI, Jae-Hyun KANG, Yong-Kuk YUN
  • Publication number: 20190181203
    Abstract: Electronic device and associated methods with multiple well areas located on a common substrate, where each well area is defined by at least three bank structures that form the side walls of the well area. Within each well area, there are at least two electrode segments where the electrode segments are separated laterally by at least one insulating bank where the insulating bank(s) are thicker than the electrode segments. There is at least one charge transporting layer completely filling the well area in direct contact and overlying both the electrode segments and the insulating bank(s). The well areas are filled using solution methods such as inkjet. Such devices have improved uniformity across the active areas.
    Type: Application
    Filed: August 14, 2017
    Publication date: June 13, 2019
    Applicants: Merck Patent GmbH, Merck Patent GmbH
    Inventors: Li Wei TAN, Peter LEVERMORE, Daniel WALKER
  • Patent number: 10316427
    Abstract: The present invention is related to a method for the production of single crystalline MgTiO3 flakes, in particular in the geikielite crystal structure, to single crystalline MgTiO3 flakes obtained by this method as well as to the use thereof, in particular as pigments in several application media.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: June 11, 2019
    Assignee: Merck Patent GmbH
    Inventor: Ryuta Suzuki
  • Patent number: 10319914
    Abstract: The invention relates to novel mixtures of substituted fullerenes, to their use in organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these fullerene mixtures.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: June 11, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Graham Morse, Jonathan Henry Wilson, Nicolas Blouin, Solene Bechu
  • Patent number: 10314841
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: June 11, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones
  • Patent number: 10315989
    Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: June 11, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Reiner Friedrich, Fanny Schooren
  • Publication number: 20190169439
    Abstract: Effect pigments based on Al2O3 flakes with high weather resistance and less photoactivity and to their use thereof in paints, industrial coatings, automotive coatings, printing inks, cosmetic formulations. The effect pigments have a ratio of the amount by weight of Al2O3 of the Al2O3 flake and the amount by weight of the metal oxide(s) of the coating layer(s) in the range of from 27:73 to 83:17 based on the total weight of the effect pigment.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 6, 2019
    Applicant: Merck Patent GmbH
    Inventors: Sabine SCHOEN, Michael JUNGNITZ, Stefan SCHLUETER, Kirsten FRITSCHE, Carsten PLUEG, Stephanie ANDES, Ulrich SCHOENEFELD
  • Publication number: 20190167591
    Abstract: Disclosed are taste-masked pharmaceutical formulations of raltegravir comprising coated API granules mixed with a screened powder excipient blend in either tablet or sachet form. The core and coated granules are produced using a Wurster process for enhanced control of particle size. Also disclosed are methods of treating HIV, e.g., in pediatric populations.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 6, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Karen Cassidy Thompson, Kimberly Nicole Kaighn, Indra Neil Mukherjee, Catherine Elizabeth Diimmler, Hedy Teppler Weiser, Christopher Mancinelli
  • Publication number: 20190167707
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: November 23, 2018
    Publication date: June 6, 2019
    Applicant: Merck Patent GmbH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Patent number: 10308645
    Abstract: The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: September 27, 2015
    Date of Patent: June 4, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
  • Patent number: 10308633
    Abstract: This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: June 4, 2019
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Qinghao Chen, Shane W. Krska, Lushi Tan, Peter E. Maligres, Jeremy Scott, Carl Baxter, Gavin William Stewart, Andrew Gibb
  • Patent number: 10308666
    Abstract: This disclosure provides methods of making certain 7-aminocephem derivatives useful in the manufacture of cephalosporin antibiotic compounds.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: June 4, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas